As per MRFR analysis, the US Human Genetics Market Size was estimated at 4.59 (USD Billion) in 2023. The US Human Genetics Market Industry is expected to grow from 5.5(USD Billion) in 2024 to 17.5 (USD Billion) by 2035. The US Human Genetics Market CAGR (growth rate) is expected to be around 11.096% during the forecast period (2025 - 2035).
The US Human Genetics Market is experiencing significant trends driven by advancements in technology, increasing awareness regarding genetic disorders, and a growing emphasis on personalized medicine. As genomic sequencing becomes more accessible and affordable, healthcare providers are increasingly integrating genetic testing into clinical practices. This integration is supported by the rise in demand for early diagnosis, which is crucial for managing inherited diseases. Additionally, the US government is enhancing funding and support for genomics research, reflecting its role in modern healthcare.
Opportunities in the market are expanding as institutions focus on developing innovative therapies and precision medicine tailored to individual genetic profiles. The establishment of partnerships between biotech firms and academic institutions is fostering research and development, particularly in areas like gene therapy and CRISPR technology. This collaboration can potentially accelerate product development and bring new solutions to the market. Recent trends include an increased focus on population genomics, which allows researchers to identify genetic variations within diverse communities, thus improving health outcomes on a broader scale.
Moreover, legislative efforts are being made to address ethical considerations related to genetic data use and privacy, which is a critical factor in gaining public trust. As consumer interest in health and genetics grows, the market is likely to see a rise in direct-to-consumer genetic testing services, leading to more informed healthcare decisions among individuals. Overall, the US Human Genetics Market is evolving rapidly, driven by technological advancements and the quest for personalized healthcare solutions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Human Genetics Market Industry is experiencing significant growth due to the increasing incidence of genetic disorders. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 33 infants is born with a genetic disorder in the United States, amounting to nearly 120,000 affected infants each year. This alarming statistic underscores the urgent need for genetic testing and therapies, thereby propelling advancements in genetic research and diagnostics.
Leading organizations such as the National Institutes of Health (NIH) are heavily invested in genetic research, working towards understanding and eventually treating these disorders. Additionally, the advocacy of groups like the Genetic Alliance has further mobilized awareness and funding for genetic conditions, creating an environment ripe for innovation and growth within the US Human Genetics Market. Furthermore, with technological advancements in genome sequencing becoming more affordable and accessible, the demand for genetic tests is expected to increase, driving the market upwards.
The integration of genetic technology into the healthcare system is significantly driving the US Human Genetics Market Industry. Hospitals and healthcare providers are increasingly adopting precision medicine, which utilizes genetic data to personalize treatment plans for patients. The American Medical Association has noted a 35% increase in the adoption of genetic testing among healthcare providers over the last three years. This trend is supported by organizations such as the Mayo Clinic, which is pioneering the use of genetic information in clinical decision-making.
As more healthcare providers integrate genetic testing into routine care, the demand for genetic services is expected to surge, further fueling market growth.
Funding for genetic research in the United States has seen a substantial rise, acting as a significant driver for the US Human Genetics Market Industry. The NIH reported an 11% increase in its funding for genomics research in the previous fiscal year, totaling over 13 billion USD dedicated to various genetic studies. This influx of funding facilitates Research and Development (R&D) of new genetic therapies and technologies, making clinical applications more advanced and effective.
Organizations like the Howard Hughes Medical Institute are also adding to this momentum by supporting innovative genetic research projects that pave the way for breakthroughs in the field.
The Application segment of the US Human Genetics Market holds a significant role in driving the industry's growth, reflecting an evolving landscape primarily shaped by advancements in genetics and personalized medicine. With the overall market expected to witness substantial growth in the coming years, various applications within this segment are making profound impacts on healthcare initiatives and consumer behavior. Wellness and E-Commerce have become increasingly intertwined, as personalized genetic testing becomes a prominent tool for consumers seeking actionable insights into their health.
This growing trend has enabled the emergence of an informed consumer base eager to engage in proactive health management, thereby enhancing the demand for genetic testing services that cater to wellness-oriented consumers. In the field of Preventive Medicine, the ability to identify genetic predispositions to certain health conditions positions genetic testing as a crucial component in healthcare strategies designed to mitigate risks and promote early intervention. By understanding genetic factors, medical professionals can create tailored preventive care plans for patients, ultimately increasing their engagement in health management activities and, consequently, improving health outcomes.
This emphasis on preventive measures is not only aligning with the broader healthcare goals of reducing costs associated with chronic diseases but also reshaping the responsibilities placed on both patients and healthcare providers in the United States. Moreover, the Diagnostic and Treatment subfield represents a key growth area within the Application segment, leveraging genetic information to refine diagnosis and pave the way for targeted therapies. By integrating genetic insights into clinical practices, healthcare practitioners can enhance diagnostic accuracy, leading to improved treatment protocols tailored to individual patient profiles.
This targeted approach is increasingly recognized as a vital method for addressing complex health issues, particularly in oncology and rare genetic disorders, where traditional therapeutic strategies may not be as effective. As discussions around ethical, legal, and social implications of genetic testing become increasingly prominent, the US Human Genetics Market must address these challenges to foster further acceptance and utilization of genetic services.
Legislative developments and policy initiatives focused on genetic privacy and equity in access to care are likely to shape the market landscape, ensuring that advancements in genetics benefit a broader population. The intersection of technology, consumer expectations, and healthcare realities fuels ongoing investment in the Application segment, indicating a robust future for the US Human Genetics Market as it continues to develop in these dynamic and complex landscapes. As a result, the growing application of genetics across various health-focused initiatives underscores the potential to revolutionize how healthcare is delivered, personalized, and optimized for diverse populations.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Human Genetics Market segment for Tests plays a pivotal role in the overall healthcare landscape, reflecting advancements in genetic technologies that drive both innovation and demand. Non-invasive prenatal testing (NIPT) stands out as particularly significant due to its ability to detect fetal anomalies early, promoting safer prenatal care. Carrier Testing has become essential for individuals and families planning for children, enabling them to make informed decisions regarding genetic disorders. Pharmacogenomic Testing is increasingly crucial, as it personalizes medication plans based on an individual’s genetic makeup, thus improving therapeutic outcomes and minimizing adverse effects.
Karyotype Testing offers valuable insights into chromosomal abnormalities, aiding in the diagnosis of various genetic conditions. Thrombophilia Testing assesses the risk of blood clotting disorders, which is vital for patient management and preventive care. The Septin 9 Biomarker Testing is gaining traction in colorectal cancer screenings, providing a non-invasive approach to early detection. Next-generation sequencing (NGS) technologies are revolutionizing the field by facilitating comprehensive genetic analyses and enabling precise genetic research.
Each of these segments contributes to the expansive landscape of the US Human Genetics Market, which showcases a strong growth trajectory fueled by increasing awareness, technological advancements, and rising incidences of genetic disorders.
The US Human Genetics Market is characterized by rapid advancements in genetic research and technology, leading to a highly competitive landscape. With the growing demand for personalized medicine, genetic testing, and clinical diagnostics, numerous companies are vying for a prominent position in this sector. The market gets further intensified by continuous innovation, strategic collaborations, and the rise of startups specializing in different aspects of genetic solutions, including oncology, reproductive health, and rare diseases. An increase in awareness about genetic disorders and the potential for targeted therapies has spurred growth in this market, giving rise to new entrants and established organizations striving to enhance their market share and influence.
Focusing on Genomic Health, the company has established a strong foothold within the US Human Genetics Market primarily due to its innovative approach in cancer genetics. The strength of Genomic Health lies in its extensive portfolio of molecular diagnostics, specifically tailored for oncology, which enables healthcare providers to make informed treatment decisions. By pioneering next-generation sequencing technologies and offering tests that are crucial for personalized therapy, the company has positioned itself as a leader in the market. The focus on accuracy, speed in testing, and the development of predictive models has fortified its competitive edge, making Genomic Health a favored choice among clinicians and patients in the US.
Myriad Genetics has also carved a significant niche within the US Human Genetics Market through its provision of various genetic testing services that focus on women's health and hereditary cancer. Their key offerings include risk assessment tests like BRCA and hereditary cancer tests, which cater to patients undergoing genetic evaluation for cancer predisposition. The strength of Myriad Genetics lies in its groundbreaking tests that facilitate preventive strategies and personalized treatment plans. The company's robust market presence is also bolstered through strategic mergers and acquisitions, allowing it to expand its capabilities and product range effectively.
Additionally, Myriad Genetics invests significantly in research and development, ensuring it remains at the forefront of genetic testing innovation. Their commitment to improving patient outcomes through accessible and reliable genetic testing further enhances their stronghold in the US market.
The US Human Genetics Market has seen significant developments recently, driven by advancements in genomic technologies and increasing demand for personalized medicine. Notable players such as Genomic Health and Myriad Genetics are expanding their product portfolios, particularly in hereditary cancer testing and precision medicine solutions. Bristol-Myers Squibb and Pfizer have been focusing on Research and Development to incorporate genetic insights into drug discovery, enhancing the efficacy of treatments.
In terms of mergers and acquisitions, Rocket Pharmaceuticals announced its acquisition of a gene therapy company in September 2023, broadening its therapeutic pipeline. Illumina continues to consolidate its position in the market, while Veracyte secured partnerships to enhance its diagnostics capabilities by integrating genomic data analysis in July 2023. Recent growth in the market valuations of these companies has also shaped investor confidence, with Thermo Fisher Scientific and GSK reporting substantial increases in stock performance due to their targeted genetic research initiatives.
Major events in the past two years, such as the unification of regulatory standards for genetic testing in December 2022, have positively influenced innovation and investment in the US Human Genetics Market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 4.59(USD Billion) |
| MARKET SIZE 2024 | 5.5(USD Billion) |
| MARKET SIZE 2035 | 17.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.096% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Genomic Health, Myriad Genetics, BristolMyers Squibb, Pfizer, Amgen, Veracyte, Cegelec, Rocket Pharmaceuticals, 23andMe, Thermo Fisher Scientific, GSK, Illumina, BioMarin Pharmaceutical, Abbott Laboratories, Regeneron Pharmaceuticals |
| SEGMENTS COVERED | Application, Test |
| KEY MARKET OPPORTUNITIES | Personalized medicine development, Genetic testing advancements, AI integration in genomics, Direct-to-consumer testing services, Gene editing technologies expansion |
| KEY MARKET DYNAMICS | Technological advancements, Growing demand for personalized medicine, Rising prevalence of genetic disorders, Increased government funding, Ethical considerations in genetic testing |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Human Genetics Market is expected to be valued at 5.5 billion USD in 2024.
By 2035, the US Human Genetics Market is projected to reach a value of 17.5 billion USD.
The CAGR for the US Human Genetics Market is estimated at 11.096% from 2025 to 2035.
The Diagnostic & Treatment application segment is expected to lead with a market value of 2.1 billion USD in 2024.
The Preventive Medicine application is projected to reach a market value of 5.85 billion USD by 2035.
Major players in the market include Genomic Health, Myriad Genetics, and Illumina among others.
The Wellness & E-Commerce application is expected to be valued at 1.65 billion USD in 2024.
Opportunities such as advancements in genetic research and increased demand for personalized medicine are driving market growth.
Challenges such as regulatory hurdles and ethical concerns may impact the growth of the US Human Genetics Market.
The Diagnostic & Treatment segment is expected to grow to 6.4 billion USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
